A review on pharmacology and therapeutic effects of empagliflozin in patients with type 2 diabetes mellitus
Abstract
Empagliflozin, a sodium glucose cotransporter 2 inhibitor, a newer class of antihyperglycemic agent, which offers the convenience of once-daily oral administration and carries a low inherent risk of hypoglycemia as a result of its unique mechanism of action, enabling it to be used as monotherapy and as an adjunct with other antidiabetic drugs. Empagliflozin has a unique mechanism of action by inhibiting glucose and sodium reabsorption in the proximal tubule of the kidney; they induce urinary glucose excretion and natriuresis. In patients with diabetes, empagliflozin results in glucose lowering, blood pressure (BP) reduction and weight loss. Empagliflozin reduced cardiovascular morbidity and mortality in patient with type 2 diabetes mellitus and established cardiovascular disease in the EMPA-REG OUTCOME trial®. The recommended starting dosage of empagliflozin is 10 mg daily. The dosage may be increased to a maximum of 25 mg/day in patients tolerating empagliflozin 10 mg/day. The most common adverse effect observed with empagliflozin (sodium glucose cotransporter 2 inhibitors) is an increment in mycotic genital infections. In this review article, we discussed the pharmacological properties, therapeutic effects, and adverse events that are associated with the administration of empagliflozin in patients with type 2 diabetes mellitus. In conclusion, empagliflozin provides greater therapeutic benefits in the management of type 2 diabetes mellitus and reduce the associated…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.